$80.43
0.76% yesterday
Nasdaq, Dec 24, 07:01 pm CET
ISIN
US36870G1058
Symbol
IRON

Gemini Therapeutics Inc Stock price

$80.43
-13.68 14.54% 1M
+25.43 46.24% 6M
+17.03 26.86% YTD
+15.42 23.72% 1Y
+64.93 418.90% 3Y
-24.57 23.40% 5Y
-22.57 21.91% 10Y
-22.57 21.91% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.61 0.76%
ISIN
US36870G1058
Symbol
IRON
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.4b
Net debt
positive
Cash
$615.9m
Shares outstanding
35.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.3
Financial Health
Equity Ratio
89.3%
Return on Equity
-24.6%
ROCE
-33.7%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-203.4m | $-241.8m
EBIT
$-203.6m | $-243.9m
Net Income
$-181.1m | $-215.3m
Free Cash Flow
$-166.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-63.1% | -86.6%
EBIT
-63.0% | -88.0%
Net Income
-75.0% | -96.9%
Free Cash Flow
-97.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-5.1
FCF per Share
$-4.7
Short interest
7.6%
Employees
125
Rev per Employee
$0.0
Show more

Is Gemini Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Gemini Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Gemini Therapeutics Inc forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Gemini Therapeutics Inc forecast:

Buy
95%
Hold
5%

Financial data from Gemini Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 54 54
79% 79%
-
- Research and Development Expense 149 149
58% 58%
-
-203 -203
63% 63%
-
- Depreciation and Amortization 0.20 0.20
18% 18%
-
EBIT (Operating Income) EBIT -204 -204
63% 63%
-
Net Profit -181 -181
75% 75%
-

In millions USD.

Don't miss a Thing! We will send you all news about Gemini Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gemini Therapeutics Inc Stock News

Neutral
Seeking Alpha
18 days ago
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
Neutral
GlobeNewsWire
19 days ago
WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASH Annual Meeting in ...
Neutral
Seeking Alpha
about one month ago
Disc Medicine, Inc. ( IRON ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants John Quisel - CEO, President & Director Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Hello, everyone. Welcome to Jefferies London Healthcare Conference 2025.
More Gemini Therapeutics Inc News

Company Profile

Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO John Quisel
Employees 125
Founded 2017
Website www.discmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today